Oromentis (Donepezil Hydrochloride)

Donepezil hydrochloride, the active ingredient in Oromentis, is an acetylcholinesterase inhibitor presented as a tablet for oral use. It is indicated for the symptomatic treatment of cognitive decline associated with Alzheimer’s disease in adults. GNH USA supplies Oromentis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oromentis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Donepezil hydrochloride is used to improve cognition by acting on the cholinergic pathways involved in memory and learning.

- Alzheimer’s disease: modestly improves cognition, behavior and daily functioning. - Vascular dementia: may provide modest benefit in cognitive performance. - Parkinson’s disease dementia: helps to alleviate cognitive symptoms associated with Parkinson’s disease.

Side effects associated with donepezil are generally mild to moderate and vary among individuals.

Common Side Effects: - Nausea - Diarrhea - Insomnia - Muscle cramps - Fatigue - Loss of appetite

Serious or Rare Side Effects: - Severe bradycardia - Gastrointestinal bleeding - Seizures - Hepatotoxicity - Allergic reactions - Psychiatric ​​   ​          ​            ​